News | August 03, 2023
Jagsonpal Pharmaceuticals posts Q1 FY2024 PAT at Rs. 7.47 Cr
The company has reported total income of Rs. 62.15 crores during the period ended June 30, 2023
The company has reported total income of Rs. 62.15 crores during the period ended June 30, 2023
The company achieved 100% capacity utilisation in the division. These accomplishments stand as a testament to the company's dedication and vision
Proposed acquisition represents meaningful step forward in Biogen’s strategy for sustainable growth
Teva will leverage Honeywell’s ‘Energy as a Service’ (EaaS) model
Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics
The 'A+' rating reflects IOL's robust business model, diversified product portfolio
Alembic has a cumulative total of 184 ANDA approvals (159 final approvals and 25 tentative approvals) from USFDA.
This patent-pending, high-efficiency chromatography media is used for the purification of novel peptide-based pharmaceuticals in the GLP-1 agonist class including type 2 diabetes and obesity treatments
Acquisition accelerates Cosette’s women’s health portfolio; with a differentiated, commercial stage, patent protected product
For Q4 ended FY23, company reported net profit of Rs. 12.56 crore as against net profit of Rs. 11.02 crore in the corresponding period last year
Subscribe To Our Newsletter & Stay Updated
